Tech Company M&A Transactions
Impact Biomedicines Acquisition
Based in San Diego, Impact Biomedicines was acquired by Celgene. Celgene disclosed that the acquisition price was $7 billion.
Transaction Overview
Company Name
Acquired By
Announced On
1/7/2018
Transaction Type
M&A
Amount
$7,000,000,000
M&A Terms
Under the terms of the agreement, Celgene will make an upfront cash payment of approximately $1.1 billion. In addition, Impact Biomedicines's shareholders are eligible to receive contingent payments based on regulatory approval and sales-based milestones. The maximum aggregate amount payable for regulatory approval milestones is $1.4 billion relating to approvals for myelofibrosis and other indications. Starting from global annual net sales of $1.0 billion, aggregate tiered sales-based milestone payments could total a maximum of $4.5 billion if global annual net sales exceed $5.0 billion.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
12526 High Bluff Dr. 260
San Diego, CA 92130
USA
San Diego, CA 92130
USA
Phone
Website
Email Address
Overview
Impact Biomedicines is pioneering the development of life-changing treatments for patients with myeloproliferative neoplasms and other cancers.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
John Hood
Chief Financial Officer
Raghu Saripalli
Chief Medical Officer
Catriona Jamieson
President
Charles McDermott
Vice President
Randy Adams
VP - Operations
Jeffery Barker
Browse more venture capital transactions:
Prev: 1/6/2018: DISCO venture capital transaction
Next: 1/8/2018: NGCodec venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on all VC transactions involving tech companies. VC transactions reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs